テイラーメイドメディスンとDDS 制癌剤投与における毒性発現の個人差とその対策
Saved in:
| Published in | Drug Delivery System Vol. 17; no. 2; pp. 113 - 118 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Japanese |
| Published |
日本DDS学会
10.03.2002
|
| Online Access | Get full text |
| ISSN | 0913-5006 1881-2732 |
| DOI | 10.2745/dds.17.113 |
Cover
| Author | 畠, 清彦 |
|---|---|
| Author_xml | – sequence: 1 fullname: 畠, 清彦 organization: 財団法人癌研究会附属病院化学療法科 |
| BookMark | eNo9j89KxDAYxIOsYHf14mMIrfmSNvlylK7_YMGDeg5JmuqWdZV2Lx5tQPExRA969iT4NnkRd3XxMjPwGwZmSAbz27knZBdoxmRe7FdVl4HMAPgGSQARUiY5G5CEKuBpQanYIsOuayjNlxASshfDY-zfYviI4TuGl9_8vArhKfavsf-K4TM-vI_H59tkszazzu-sfUQujw4vypN0cnZ8Wh5M0gaYMKlAL5gSzuUC0aEo0NW-hsJKIaWy1iprlJKqljXywq9KrDLWKWkQqTJ8RMq_3aZbmCuv79rpjWnvtWkXUzfzevkRFAoNUrO1AP-n7tq0ujH8B7gPW4U |
| ContentType | Journal Article |
| Copyright | 日本DDS学会 |
| Copyright_xml | – notice: 日本DDS学会 |
| DOI | 10.2745/dds.17.113 |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1881-2732 |
| EndPage | 118 |
| ExternalDocumentID | article_dds1986_17_2_17_2_113_article_char_ja |
| GroupedDBID | .55 3O- 53G 5GY ACIWK ACPRK AFRAH AL- ALMA_UNASSIGNED_HOLDINGS AUIBY CS3 JSF JSH OK1 RJT RZJ X7M |
| ID | FETCH-LOGICAL-j126a-68e6296cc4688c8658cfef15b76779bbb9ba9979f7f835e688c2dabc97a8809a3 |
| ISSN | 0913-5006 |
| IngestDate | Wed Sep 03 06:29:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 2 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j126a-68e6296cc4688c8658cfef15b76779bbb9ba9979f7f835e688c2dabc97a8809a3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/dds1986/17/2/17_2_113/_article/-char/ja |
| PageCount | 6 |
| ParticipantIDs | jstage_primary_article_dds1986_17_2_17_2_113_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2002/03/10 |
| PublicationDateYYYYMMDD | 2002-03-10 |
| PublicationDate_xml | – month: 03 year: 2002 text: 2002/03/10 day: 10 |
| PublicationDecade | 2000 |
| PublicationTitle | Drug Delivery System |
| PublicationTitleAlternate | DDS |
| PublicationYear | 2002 |
| Publisher | 日本DDS学会 |
| Publisher_xml | – name: 日本DDS学会 |
| References | 28) Loni L, Tacca MD, Danesi R : Pharmacogenetics of anticancer drugs in non-Hodgkin's lymphomas. Br J Cancer 85 : 1425-1431, 2001. 17) Del Villar K, Urano J, Guo L, Tamanoi F : A mutant form of human protein farnesy-ltransferase exhibits increased resistance to franesyltransferase inhibitors. J Biol Chem 274 : 27010-27017, 1999. 35) Nishikawa M, Nagatomi H, Chang BJ, Sato E, Inoue M : Targetting superoxide dismutase to renal tubule cells inhibits mitochondrial injury and renal dysfunction induced by cisplatin. Arch Biochem Biophys 387 : 78-84, 2001. 30) Arndt D, Zeisig R, Bechtel D, Fichtner I : Liposomal bleomycin : increased therapeutic activity and decreased pulmonary toxicity in mice. Drug Deliv 8 : 1-7, 2001. 33) Mizumura Y, Matsumura Y, Hamaguchi T et al. : Cisplatin-incorporated polymeric micelle eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res 92 : 328-336, 2001. 19)畠, 清彦, 三嶋雄二 : アミノペプチダーぜ阻害剤とアポトーシス. 血液腫瘍科 42 : 443-448, 2001. 22) Mishima Y, Terui Y, Tomizuka H, Mori M, Uwai M, Ueda M, Tanaka M, Yamada M, Hayasawa H, Ozawa K, Horikoshi N, Hatake K : CD 13/aminopeptidase-N is resistance mechanism for endothelial interleukin-8 inducing apoptosis. ICCSA supplement. Cell-surface arninope-ptidases : Basic and clinical aspects. Elsevier Science ed. by Mizutani S et al., 2001, p 177-184. 26) Certa U, Seider M, Padovan E, Spagnoli GC : High density oligonucleotide array analysis of interferon alpha 2 a sensitivity and transcriptional response in melanoma cells. Br J Cancer 85 : 107-114, 2901. 36) Nilsson F, Kosmehl H, Zardi L, Neri D : Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61 : 711-716, 2001. 23) Shah AA, Thjodleifsson B, Murray FE et al. : Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury : a comparison of nimesulide and naproxen. Gut 48 : 339-346, 2001. 10) Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M : CD 20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia : further regulation by CD 55 and CD 59. Blood 98 : 3383-3389, 2001. 21) Hahida H, Takahayashi A, Kanai M et al. : Aminopeptidase N is involved in cell motility and angiogenesis : Its clinical significance in human colon cancer. Gastroenterology 2002 (in press). 34) Senderowicz AM : Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19 : 6600-6606, 2000. 7) Schneider JW, Chang AY, Rocco TP : Cardiotoxicity in signal transduction therapeutics : erbB 2 antibodies and the heart. Semin Oncol 5 (suppl. 16) : 18-26, 2001. 24) De Win N, Dekker M, Claij N, Jansen L, van Klink Y, Radman M, Riggins G, van der Valk M, van'n Wout K, te Riele H : HNPCC-like cancer predisposition in mice through simultanous loss of MSH 2 and MSH 6 mismatchrepair protein functions. Nat Genet 23 : 359-362, 1999. 12) Krystal GW : Mechanisms of resistance to imatinib (STI 571) and protects for combination with conventional chemotherapeutic agents. Drug Resist Update 4 : 16-21, 2001. 15) Demetri GD : Targeting c-kit mutations in solid tumors : scientific rationale and novel therapeutic options. Semin Oncol 28 : (5 suppl. 17) : 17-26, 2001. 20) Kato H, Konaka C, Tsuboi M et al. : A randomized phase III study comparing Ubenimex (Bestatin) versus placebo as postoperative adjuvant treatment in patients with stage I squamous cell lung cancer. Proc ASCO 307 a, 2001. 29) Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshirkg NI, Lotem M, Brufman G, Gabizon A : Correlation of toxicity with pharmacokinetics of pegylated liposomal doxoruhicin (Doxil) in metastatic breast carcinoma. Cancer 89 : 1037-1047, 2000. 11) Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL : Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutations or amplification. Science 293 : 876-880, 2001. 1) Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, Okano T, Sakurai Y, Kataoka K : Development of the polymer micelle carrier system for doxorubicin. J Control Release 74 : 295-302, 2001. 14) van Oosterorn AT, Judson I, Verweij J, Stroobants S et al. : Safety and efficacy of irnatinib (STI 571) in metastatic gastrointestinal tumors : a phase I study. Lancet 358 : 1421-1423, 2001. 9) Pichert G, Schmitz SH, Hess U, Cerny T, Cogliatti SB, Betticher D, Stupp R, Schmitter D, Stahel RA, Ghielmini M : Weekly X 4 induction therapy with the anti-CD 20 antibody rituximab : Effect o circulating t(14 ; 18) +follicular lymphoma cells. Clin Lymphoma 1 : 293-297, 2001. 18) Moasser MM, Basso A, Averbuch SD, Rosen N : The tyrosine kinase inhibitor (Iressa) inhibits HER 2-driven signaling and suppresses the growth of HER 2-overexpressing tumour cells. Cancer Res 61 : 7184-7188, 2001. 3) Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E : A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85 : 2293-2297, 2001. 5) Kawai K, Hinotsu S, Tomobe M, Akaza H : Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Jpn J Clin Oncol 28 : 546-550, 1998. 4) Bloor AJ, Seale JR, Marcus RE : Two cases of fatal bleomycin pneumonitis complicating the treatment of non-Hodkin's lymphoma. Clin Lab Haematol 20 : 119-121, 1998. 32) Tulpule A, Rarick MU, Kolitz J, Berstein J, Myers A, Buchanan LA, Espina BM, Traynor A, Letzer J, Justice GR, McDonald D, Roberts L, Boswell W, Nathwani B, Levine AM : Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol 12 : 457-462, 2001. 27) Kaminski N, Allard J, Heller RA : Use of oligonucleotide arrays to analyze drug toxicity. Ann NY Acad Scie 919 : 1-8, 2000. 25) Liu J, Chen H, Miller DS, Saavendra JE, Keefer LK, Johnson DR, Klassen CD, Waaikes MP : Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol 60 : 302-309, 2001. 6) Rewinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BC, Cornblath DR, Donehower RC : Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor : neuromuscular toxicity is dose-limiting. J Clin Oncol 11 : 2010-2020, 1993. 8) 伊藤良則·他 : 投稿準備中. 2) Chakrabarti KB, Hopewell JW, Wilding D, Plowman PN : Modification of doxorubicin-induced cardiotoxicity : effect of essential fatty acids and ICRF-187 (dextrazoxane). Eur J Cancer 37 : 1435-1442, 2001. 31) Treat J, Damjanov N, Huang C, Zrada S, Rahman A : Liposomal-encapsulated chemotherapy : preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology 15(5 suppl. 7) : 44-48, 2001. 13) Tipping AJ, Mahon FX, Laoarde V, Goldman JM, Melo JV : Restroation of sensitivity to STI 571 in STI 571-resistant chronic myeloid leukemia cells. Blood 98 : 3864-3867, 2001. 16) McClelland RA, Barrow D, Madden TA, Dutknwski CM, Pamment J, Knowden JM, Gee JM, Nicholson RI : Enhanced epidermal growth factor receptor signaling in the breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex). Endocrinology 142 : 2776-2788, 2001. |
| References_xml | – reference: 17) Del Villar K, Urano J, Guo L, Tamanoi F : A mutant form of human protein farnesy-ltransferase exhibits increased resistance to franesyltransferase inhibitors. J Biol Chem 274 : 27010-27017, 1999. – reference: 7) Schneider JW, Chang AY, Rocco TP : Cardiotoxicity in signal transduction therapeutics : erbB 2 antibodies and the heart. Semin Oncol 5 (suppl. 16) : 18-26, 2001. – reference: 29) Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshirkg NI, Lotem M, Brufman G, Gabizon A : Correlation of toxicity with pharmacokinetics of pegylated liposomal doxoruhicin (Doxil) in metastatic breast carcinoma. Cancer 89 : 1037-1047, 2000. – reference: 23) Shah AA, Thjodleifsson B, Murray FE et al. : Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury : a comparison of nimesulide and naproxen. Gut 48 : 339-346, 2001. – reference: 13) Tipping AJ, Mahon FX, Laoarde V, Goldman JM, Melo JV : Restroation of sensitivity to STI 571 in STI 571-resistant chronic myeloid leukemia cells. Blood 98 : 3864-3867, 2001. – reference: 25) Liu J, Chen H, Miller DS, Saavendra JE, Keefer LK, Johnson DR, Klassen CD, Waaikes MP : Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol 60 : 302-309, 2001. – reference: 9) Pichert G, Schmitz SH, Hess U, Cerny T, Cogliatti SB, Betticher D, Stupp R, Schmitter D, Stahel RA, Ghielmini M : Weekly X 4 induction therapy with the anti-CD 20 antibody rituximab : Effect o circulating t(14 ; 18) +follicular lymphoma cells. Clin Lymphoma 1 : 293-297, 2001. – reference: 31) Treat J, Damjanov N, Huang C, Zrada S, Rahman A : Liposomal-encapsulated chemotherapy : preliminary results of a phase I study of a novel liposomal paclitaxel. Oncology 15(5 suppl. 7) : 44-48, 2001. – reference: 10) Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M : CD 20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia : further regulation by CD 55 and CD 59. Blood 98 : 3383-3389, 2001. – reference: 12) Krystal GW : Mechanisms of resistance to imatinib (STI 571) and protects for combination with conventional chemotherapeutic agents. Drug Resist Update 4 : 16-21, 2001. – reference: 19)畠, 清彦, 三嶋雄二 : アミノペプチダーぜ阻害剤とアポトーシス. 血液腫瘍科 42 : 443-448, 2001. – reference: 30) Arndt D, Zeisig R, Bechtel D, Fichtner I : Liposomal bleomycin : increased therapeutic activity and decreased pulmonary toxicity in mice. Drug Deliv 8 : 1-7, 2001. – reference: 35) Nishikawa M, Nagatomi H, Chang BJ, Sato E, Inoue M : Targetting superoxide dismutase to renal tubule cells inhibits mitochondrial injury and renal dysfunction induced by cisplatin. Arch Biochem Biophys 387 : 78-84, 2001. – reference: 27) Kaminski N, Allard J, Heller RA : Use of oligonucleotide arrays to analyze drug toxicity. Ann NY Acad Scie 919 : 1-8, 2000. – reference: 26) Certa U, Seider M, Padovan E, Spagnoli GC : High density oligonucleotide array analysis of interferon alpha 2 a sensitivity and transcriptional response in melanoma cells. Br J Cancer 85 : 107-114, 2901. – reference: 4) Bloor AJ, Seale JR, Marcus RE : Two cases of fatal bleomycin pneumonitis complicating the treatment of non-Hodkin's lymphoma. Clin Lab Haematol 20 : 119-121, 1998. – reference: 5) Kawai K, Hinotsu S, Tomobe M, Akaza H : Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Jpn J Clin Oncol 28 : 546-550, 1998. – reference: 18) Moasser MM, Basso A, Averbuch SD, Rosen N : The tyrosine kinase inhibitor (Iressa) inhibits HER 2-driven signaling and suppresses the growth of HER 2-overexpressing tumour cells. Cancer Res 61 : 7184-7188, 2001. – reference: 15) Demetri GD : Targeting c-kit mutations in solid tumors : scientific rationale and novel therapeutic options. Semin Oncol 28 : (5 suppl. 17) : 17-26, 2001. – reference: 36) Nilsson F, Kosmehl H, Zardi L, Neri D : Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61 : 711-716, 2001. – reference: 2) Chakrabarti KB, Hopewell JW, Wilding D, Plowman PN : Modification of doxorubicin-induced cardiotoxicity : effect of essential fatty acids and ICRF-187 (dextrazoxane). Eur J Cancer 37 : 1435-1442, 2001. – reference: 16) McClelland RA, Barrow D, Madden TA, Dutknwski CM, Pamment J, Knowden JM, Gee JM, Nicholson RI : Enhanced epidermal growth factor receptor signaling in the breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex). Endocrinology 142 : 2776-2788, 2001. – reference: 22) Mishima Y, Terui Y, Tomizuka H, Mori M, Uwai M, Ueda M, Tanaka M, Yamada M, Hayasawa H, Ozawa K, Horikoshi N, Hatake K : CD 13/aminopeptidase-N is resistance mechanism for endothelial interleukin-8 inducing apoptosis. ICCSA supplement. Cell-surface arninope-ptidases : Basic and clinical aspects. Elsevier Science ed. by Mizutani S et al., 2001, p 177-184. – reference: 32) Tulpule A, Rarick MU, Kolitz J, Berstein J, Myers A, Buchanan LA, Espina BM, Traynor A, Letzer J, Justice GR, McDonald D, Roberts L, Boswell W, Nathwani B, Levine AM : Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol 12 : 457-462, 2001. – reference: 24) De Win N, Dekker M, Claij N, Jansen L, van Klink Y, Radman M, Riggins G, van der Valk M, van'n Wout K, te Riele H : HNPCC-like cancer predisposition in mice through simultanous loss of MSH 2 and MSH 6 mismatchrepair protein functions. Nat Genet 23 : 359-362, 1999. – reference: 8) 伊藤良則·他 : 投稿準備中. – reference: 6) Rewinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BC, Cornblath DR, Donehower RC : Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor : neuromuscular toxicity is dose-limiting. J Clin Oncol 11 : 2010-2020, 1993. – reference: 33) Mizumura Y, Matsumura Y, Hamaguchi T et al. : Cisplatin-incorporated polymeric micelle eliminate nephrotoxicity, while maintaining antitumor activity. Jpn J Cancer Res 92 : 328-336, 2001. – reference: 34) Senderowicz AM : Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19 : 6600-6606, 2000. – reference: 11) Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL : Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutations or amplification. Science 293 : 876-880, 2001. – reference: 21) Hahida H, Takahayashi A, Kanai M et al. : Aminopeptidase N is involved in cell motility and angiogenesis : Its clinical significance in human colon cancer. Gastroenterology 2002 (in press). – reference: 1) Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, Okano T, Sakurai Y, Kataoka K : Development of the polymer micelle carrier system for doxorubicin. J Control Release 74 : 295-302, 2001. – reference: 28) Loni L, Tacca MD, Danesi R : Pharmacogenetics of anticancer drugs in non-Hodgkin's lymphomas. Br J Cancer 85 : 1425-1431, 2001. – reference: 20) Kato H, Konaka C, Tsuboi M et al. : A randomized phase III study comparing Ubenimex (Bestatin) versus placebo as postoperative adjuvant treatment in patients with stage I squamous cell lung cancer. Proc ASCO 307 a, 2001. – reference: 3) Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Gamelin E : A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85 : 2293-2297, 2001. – reference: 14) van Oosterorn AT, Judson I, Verweij J, Stroobants S et al. : Safety and efficacy of irnatinib (STI 571) in metastatic gastrointestinal tumors : a phase I study. Lancet 358 : 1421-1423, 2001. |
| SSID | ssj0048811 ssib058492641 ssib007483962 ssib001535732 ssib002484529 |
| Score | 1.5578283 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 113 |
| Subtitle | 制癌剤投与における毒性発現の個人差とその対策 |
| Title | テイラーメイドメディスンとDDS |
| URI | https://www.jstage.jst.go.jp/article/dds1986/17/2/17_2_113/_article/-char/ja |
| Volume | 17 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Drug Delivery System, 2002/03/10, Vol.17(2), pp.113-118 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Li9RAEG6G9eJFXB_4Jgd7D7IZ00k_wUtmJrIoyoqzsLfQyaSFQVbZnTnM3pyA4t0_IHrQsyfBf5M_YnXes3hwFUJTqXRnevprKl-nqyoI3U-MENp6T3mB5C6V_szVlGh3JvwgM6kvROmb8-w53zugTw7Z4WDwqee1tFwkw_T0j3El_4Iq6ABXGyV7DmTbm4ICZMAXSkAYyr_CGEcBlnDwUvBxSGtNqGphNG405GwdqTYvwSGaOkEtjNr7VBqCQzmZvOwz2snx8hVYrdfWv2NVJ0BvUMSRwIrh0LNA4ojjkcSS4Yjh0QSHfOONg--W7mvtHLHVlcAhK4UxDsfww7ZpaJviiNr_psL-q0YSuMzz6pTXlaGVktiwoE1LLHozzu-ZVVLFq9ZPaFJZ7LPGH9bXNk_GbHYyJGLYNtlIpl1DFUMloiSPiYj9uiBB3Fy1AW_xHFj3BZir5eb_0xf9vcWAiX7SNyrt7nV7LiiQzi4JIzA8BayzdTwCi1l-FbodlSppru39w67vQIjmsDxoXAtLtjO9jC7VyxQnrLq6jQZzfQXt7Fd5zle7zrQL2zvZdXac_S4D-uoqelDk74v11yL_XuS_ivxzKX-0Qv6hWH8p1j-L_Efx7hsgeg0dPI6m4z23_iiHOyc-1y6XGfcVT1PKpUwlENjUZIawRHAhVJIkKtFKCWWEAXKf2Ur-TCepEhoeFUoH19HW0Zuj7AZyUk8Yo6mB0TGUMiNZCiMLlFVLL6Esu4keVWMQv60yr8Tngu_W_zW_jS52k_8O2locL7O7QEAXyb1yPvwGRHly9g |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E3%83%86%E3%82%A4%E3%83%A9%E3%83%BC%E3%83%A1%E3%82%A4%E3%83%89%E3%83%A1%E3%83%87%E3%82%A3%E3%82%B9%E3%83%B3%E3%81%A8DDS&rft.jtitle=Drug+Delivery+System&rft.au=%E7%95%A0%2C+%E6%B8%85%E5%BD%A6&rft.date=2002-03-10&rft.pub=%E6%97%A5%E6%9C%ACDDS%E5%AD%A6%E4%BC%9A&rft.issn=0913-5006&rft.eissn=1881-2732&rft.volume=17&rft.issue=2&rft.spage=113&rft.epage=118&rft_id=info:doi/10.2745%2Fdds.17.113&rft.externalDocID=article_dds1986_17_2_17_2_113_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0913-5006&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0913-5006&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0913-5006&client=summon |